Enhanced Dermal Delivery of Flurbiprofen Nanosuspension Based Gel: Development and Ex Vivo Permeation, Pharmacokinetic Evaluations

[41] Li S(2018)Flurbiprofen concentration in soft tissues is higher after topical application than after oral administration Eur J Pharm Sci 122 1278-220

[42] Hao K(2019)Selective follicular targeting by modification of the particle sizes Pharm Dev Technol 24 101371-728

[43] Xia D(2020)Nanoparticles–an efficient carrier for drug delivery into the hair follicles Journal of Drug Delivery Science and Technology. 55 171-423

[44] Quan P(2004)A novel concept of overcoming the skin barrier using augmented liquid nanocrystals: box-Behnken optimization, ex vivo and Int J Pharm 275 189-522

[45] Piao H(2002) evaluation Pharm Res 19 217-747

[46] Piao H(2016)Enhanced transdermal delivery of meloxicam by nanocrystals: preparation, Int J Pharm 498 209-1038

[47] Sun S(2013) and Int J Pharm 443 718-234

[48] Yin Y(2012) evaluation Eur J Pharm Sci 47 2943-12

[49] Cui F(2014)Preparation and Int J Nanomedicine 9 417-152

[50] Leitner J(2005)/ Drug Dev Ind Pharm 31 514-140

[41] Li S(2018)Flurbiprofen concentration in soft tissues is higher after topical application than after oral administration Eur J Pharm Sci 122 1278-220

[42] Hao K(2019)Selective follicular targeting by modification of the particle sizes Pharm Dev Technol 24 101371-728

[43] Xia D(2020)Nanoparticles–an efficient carrier for drug delivery into the hair follicles Journal of Drug Delivery Science and Technology. 55 171-423

[44] Quan P(2004)A novel concept of overcoming the skin barrier using augmented liquid nanocrystals: box-Behnken optimization, ex vivo and Int J Pharm 275 189-522

[45] Piao H(2002) evaluation Pharm Res 19 217-747

[46] Piao H(2016)Enhanced transdermal delivery of meloxicam by nanocrystals: preparation, Int J Pharm 498 209-1038

[47] Sun S(2013) and Int J Pharm 443 718-234

[48] Yin Y(2012) evaluation Eur J Pharm Sci 47 2943-12

[49] Cui F(2014)Preparation and Int J Nanomedicine 9 417-152

[50] Leitner J(2005)/ Drug Dev Ind Pharm 31 514-140